Table 1.
AUROC of genomic metrics as a continuous variable
| AUROC (95% CI) | OncoScan n = 120 |
Infinium CytoSNP-850K n = 106 |
|---|---|---|
| With deleterious BRCA m | ||
| LOH versus BRCAm | 0.76 (0.62–0.89) | 0.64 (0.46–0.82) |
| TAI versus BRCAm | 0.78 (0.65–0.90) | 0.72 (0.57–0.87) |
| LST versus BRCAm | 0.89 (0.82–0.96) | 0.83 (0.70–0.95) |
| HRDa versus BRCAm | 0.87 (0.77–0.97) | 0.75 (0.61–0.89) |
| With the clinically validated HRD test (cut-off, 42) | ||
| LOH versus clinically validated HRD test | 0.85 (0.77–0.92) | 0.78 (0.67–0.88) |
| TAI versus clinically validated HRD test | 0.86 (0.79–0.93) | 0.86 (0.78–0.93) |
| LST versus clinically validated HRD test | 0.89 (0.82–0.95) | 0.95 (0.90–0.99) |
| HRDa versus clinically validated HRD test | 0.92 (0.87–0.97) | 0.91 (0.85–0.96) |
aHRD is the sum of LOH, TAI, and LST
Abbreviations: AUROC, area under the receiver operating characteristic; BRCAm, mutation in BRCA1, BRCA2, or both; CI, confidence interval; HRD, homologous recombination deficiency; LOH, loss of heterozygosity; LST, large-scale state transition; TAI, telomeric-allelic imbalance number